Base de dados : MEDLINE
Pesquisa : C04.557.465.510.350 [Categoria DeCS]
Referências encontradas : 927 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 93 ir para página                         

  1 / 927 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28803748
[Au] Autor:Nasioudis D; Chapman-Davis E; Frey MK; Caputo TA; Holcomb K
[Ad] Endereço:Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA; Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Electronic address: dimitrios.nasioudis@uphs.upenn.edu.
[Ti] Título:Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base.
[So] Source:Gynecol Oncol;147(2):296-301, 2017 Nov.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the clinico-pathological characteristics, management and prognosis of women diagnosed with ovarian yolk sac tumors (OYSTs). METHODS: The U.S National Cancer Data Base was queried for women diagnosed with OYST between 2004 and 2014. Overall survival (OS) was calculated following generation of Kaplan-Meir curves. Univariate analysis was performed with the log-rank test. A Cox model was constructed to determine independent predictors of mortality. RESULTS: A total of 561 women were identified with a median age of 23years. The majority (58.5%) had early stage (I-II), while 29.6% and 11.9% had stage III and IV disease respectively. Five-year OS for women with stage I, II, III and IV disease were 94.8%, 97.1%, 70.9% and 51.6% respectively, p<0.001. Better 5-yr OS was observed for adolescents (94.4%) and young adults (89.3%) compared to older premenopausal (67.6%) and postmenopausal women (30.6%), p<0.001. Omentectomy, hysterectomy and lymph node sampling/dissection (LND) were not associated with better OS. Women who received adjuvant chemotherapy had superior OS compared to those who did not, p=0.016. Early disease stage, younger age and receipt of adjuvant chemotherapy, but not LND were independently associated with better mortality. CONCLUSIONS: Women with OYST commonly present with early stage disease. Administration of adjuvant chemotherapy, early stage and younger age are associated with superior outcomes.
[Mh] Termos MeSH primário: Tumor do Seio Endodérmico/diagnóstico
Tumor do Seio Endodérmico/terapia
Neoplasias Ovarianas/diagnóstico
Neoplasias Ovarianas/terapia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Criança
Pré-Escolar
Bases de Dados Factuais
Tumor do Seio Endodérmico/mortalidade
Feminino
Seres Humanos
Lactente
Meia-Idade
Estadiamento de Neoplasias
Neoplasias Ovarianas/mortalidade
Prognóstico
Estados Unidos/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE


  2 / 927 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28315695
[Au] Autor:Taher A; Denic N; Kalimuthu SN; Chetty R
[Ad] Endereço:Department of Pathology, Health Sciences Centre, Eastern Health and Memorial University Newfoundland, St John's, Newfoundland and Labrador A1B 3V6, Canada.
[Ti] Título:An unusual primary malignant tumor of the stomach: fetal gutlike gastric adenocarcinoma with "blastoma"-like component.
[So] Source:Hum Pathol;67:176-180, 2017 Sep.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:An unusual case of a polypoid, malignant gastric tumor in a 62-year-old man is presented. Endoscopy and subsequent polypectomy revealed an 8.5 × 6.5 × 4.5-cm lesion in the body of the stomach. Microscopy showed surface dysplasia with an invasive adenocarcinoma displaying prominent tubulopapillary areas composed of large vacuolated cells, pleomorphic nuclei, and occasional cytoplasmic hyaline globules. This component then blended with tubular structures lined by more primitive-appearing vacuolated cells embedded within a stroma made up of cellular primitive, high-grade blastemalike areas and less cellular, more pleomorphic foci with spindle and several bizarre, large cells. Immunohistochemistry showed the adenocarcinoma and primitive tubules to be strongly SALL4 and epithelial marker positive but with only focal expression of α-fetoprotein and glypican-3. The stromal component made up of blastemalike areas displayed strong immunoreactivity for glypican-3. The pleomorphic stromal areas were negative for all markers, including epithelial and muscle markers. The overall morphology and expression of primitive oncofetal proteins, especially SALL4 and glypican-3, are in keeping with this being a primitive adenocarcinoma showing fetal gutlike differentiation with an accompanying blastomalike component, a combination not previously described in a primary gastric cancer.
[Mh] Termos MeSH primário: Adenocarcinoma/patologia
Tumor do Seio Endodérmico/patologia
Neoplasias Complexas Mistas/patologia
Neoplasias Gástricas/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma/química
Adenocarcinoma/cirurgia
Biomarcadores Tumorais/análise
Biópsia
Diferenciação Celular
Tumor do Seio Endodérmico/química
Tumor do Seio Endodérmico/cirurgia
Glipicanas/análise
Seres Humanos
Imuno-Histoquímica
Masculino
Meia-Idade
Neoplasias Complexas Mistas/química
Neoplasias Complexas Mistas/cirurgia
Neoplasias Gástricas/química
Neoplasias Gástricas/cirurgia
Fatores de Transcrição/análise
alfa-Fetoproteínas/análise
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AFP protein, human); 0 (Biomarkers, Tumor); 0 (GPC3 protein, human); 0 (Glypicans); 0 (SALL4 protein, human); 0 (Transcription Factors); 0 (alpha-Fetoproteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170320
[St] Status:MEDLINE


  3 / 927 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28262583
[Au] Autor:Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
[Ad] Endereço:Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany. Electronic address: Stefanie.Zschaebitz@med.uni-heidelberg.de.
[Ti] Título:Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
[So] Source:Eur J Cancer;76:1-7, 2017 May.
[Is] ISSN:1879-0852
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Treatment options for patients with platinum refractory metastatic germ cell tumours (GCT) relapsing after high-dose chemotherapy and autologous stem cell transplantation are limited and survival is poor. Antibodies directed against programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) are currently assessed within clinical trials. We present updated data on our experience with checkpoint inhibitors as a compassionate use off-label treatment attempt for highly-pretreated patients with GCT and provide an overview of the current literature on PD-L1 expression in this rare tumour entity. PATIENTS AND METHODS: We analysed all patients with platinum refractory GCT treated with checkpoint inhibitors at our institutions between 2015 and 2017. Data were retrieved retrospectively from the patient charts. RESULTS: Seven patients were treated with nivolumab or pembrolizumab. Four patients received single-dose treatment and died shortly afterwards due to tumour progression; the remaining three patients received treatment for at least 6 months. No significant treatment toxicity was observed. Long-term tumour response was achieved in two of the three patients, both of them highly positive for PD-L1 staining. INTERPRETATION: We consider checkpoint inhibition to be efficient in carefully selected patients with platinum refractory GCT. However, predictive markers associated with tumour response are not yet known and larger prospective clinical trials are warranted.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias do Mediastino/tratamento farmacológico
Recidiva Local de Neoplasia/tratamento farmacológico
Neoplasias Embrionárias de Células Germinativas/tratamento farmacológico
Neoplasias Testiculares/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Coriocarcinoma não Gestacional/diagnóstico por imagem
Coriocarcinoma não Gestacional/tratamento farmacológico
Coriocarcinoma não Gestacional/metabolismo
Coriocarcinoma não Gestacional/secundário
Cisplatino/uso terapêutico
Ensaios de Uso Compassivo
Tumor do Seio Endodérmico/diagnóstico por imagem
Tumor do Seio Endodérmico/tratamento farmacológico
Tumor do Seio Endodérmico/metabolismo
Tumor do Seio Endodérmico/secundário
Etoposídeo/uso terapêutico
Seres Humanos
Ifosfamida/uso terapêutico
Neoplasias Pulmonares/diagnóstico por imagem
Neoplasias Pulmonares/secundário
Masculino
Neoplasias do Mediastino/metabolismo
Neoplasias do Mediastino/patologia
Meia-Idade
Neoplasias Embrionárias de Células Germinativas/diagnóstico por imagem
Neoplasias Embrionárias de Células Germinativas/metabolismo
Neoplasias Embrionárias de Células Germinativas/secundário
Compostos de Platina/administração & dosagem
Receptor de Morte Celular Programada 1/metabolismo
Estudos Retrospectivos
Seminoma/diagnóstico por imagem
Seminoma/tratamento farmacológico
Seminoma/metabolismo
Seminoma/secundário
Transplante de Células-Tronco
Teratoma
Neoplasias Testiculares/metabolismo
Neoplasias Testiculares/patologia
Tomografia Computadorizada por Raios X
Transplante Autólogo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (PDCD1 protein, human); 0 (Platinum Compounds); 0 (Programmed Cell Death 1 Receptor); 31YO63LBSN (nivolumab); 6PLQ3CP4P3 (Etoposide); DPT0O3T46P (pembrolizumab); Q20Q21Q62J (Cisplatin); UM20QQM95Y (Ifosfamide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE


  4 / 927 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28249923
[Au] Autor:Kojima YA; Assylbekova B; Zhao B; Nugent E; Brown RE
[Ad] Endereço:Department of Pathology and Laboratory Medicine, UT Health-McGovern Medical School, Houston, TX, USA Yumi.a.kojima@uth.tmc.edu.
[Ti] Título:Morphoproteomics Identifies the EZH2 and SIRT1 Pathways as Potential Blocks to Differentiation in Yolk Sac Tumor of the Ovary and Provides Therapeutic Options: a Case Study.
[So] Source:Ann Clin Lab Sci;47(1):88-91, 2017 Jan.
[Is] ISSN:1550-8080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Yolk sac tumor of the ovary is a rare but highly malignant and aggressive germ cell tumor. The objective of this case study of an ovarian yolk sac tumor was to identify putative pathways that are known to pose a block in differentiation, both in early embryogenesis and in tumorigenesis, that might be amenable to low toxicity therapies designed to promote differentiation to a more benign state and prevent recurrent disease in such tumors. The enhancer of Zeste homolog 2 (EZH2), a histone methyl transferase, and silent mating type information regulation 2 homolog 1 (SIRT1), a NAD+ histone deacetylase, are two such pathways.
[Mh] Termos MeSH primário: Diferenciação Celular
Tumor do Seio Endodérmico/metabolismo
Tumor do Seio Endodérmico/patologia
Proteína Potenciadora do Homólogo 2 de Zeste/metabolismo
Neoplasias Ovarianas/metabolismo
Proteômica/métodos
Transdução de Sinais
Sirtuína 1/metabolismo
[Mh] Termos MeSH secundário: Adulto
Biomarcadores Tumorais/metabolismo
Feminino
Seres Humanos
Neoplasias Ovarianas/patologia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein); EC 3.5.1.- (Sirtuin 1)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170313
[Lr] Data última revisão:
170313
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE


  5 / 927 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28215183
[Au] Autor:van den Akker M; Vervloessem D; Huybrechs A; Declercq S; van der Werff Ten Bosch J
[Ad] Endereço:Department of Pediatrics, ZNA Queen Paola Children's Hospital, Antwerp, Belgium. machielvdakker@gmail.com.
[Ti] Título:Yolk sac tumor in the abdominal wall of an 18-month-old girl: a case report.
[So] Source:J Med Case Rep;11(1):47, 2017 Feb 20.
[Is] ISSN:1752-1947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pediatric germ cell tumors account for approximately 3.5 % of all childhood cancers for children under the age of 15 years. Up to one-third are extragonadal neoplasms. Germ cell tumors are a heterogeneous group of malignant tumors with a wide variety of histopathological features. Yolk sac tumor is the predominant variant in newborns and younger children. We report for the first time, the presentation of a primary yolk sac tumor in the abdominal wall of a small child. CASE PRESENTATION: An 18-month-old white girl underwent resection of a small, round subcutaneous lump (1.5×1.3×0.8 cm) of the abdominal wall in her right hypochondriac region. The histopathology was compatible with yolk sac tumor. Her alpha-fetoprotein was initially elevated but normalized after the resection. Magnetic resonance imaging of her abdomen was normal. The surgeon decided to observe and follow her alpha-fetoprotein level closely. One year after resection a local recurrence appeared and her alpha-fetoprotein rose to 58 ng/mL. The surgeon performed a wide resection of the lesion with normalization of her alpha-fetoprotein. Follow-up consisted of measuring alpha-fetoprotein, clinical evaluation, and abdominal ultrasound. CONCLUSIONS: Clinicians should be aware that a yolk sac tumor can present in an unusual extragonadal place, for example in this case it was subcutaneous. In some cases, conservative treatment can be carried out with careful monitoring of the patient and their alpha-fetoprotein.
[Mh] Termos MeSH primário: Parede Abdominal/patologia
Tumor do Seio Endodérmico/patologia
Recidiva Local de Neoplasia/patologia
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/análise
Tratamento Conservador
Tumor do Seio Endodérmico/diagnóstico
Feminino
Seres Humanos
Lactente
Imagem por Ressonância Magnética
Recidiva Local de Neoplasia/cirurgia
Ultrassonografia
alfa-Fetoproteínas/análise
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (alpha-Fetoproteins)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170720
[Lr] Data última revisão:
170720
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170221
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1216-4


  6 / 927 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28202048
[Au] Autor:Hirakawa H; Nakashima C; Nakamura T; Masuda M; Funakoshi T; Nakagawa S; Horimatsu T; Matsubara K; Muto M; Kimura S; Sueoka-Aragane N
[Ad] Endereço:Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Naoko Sueoka-Aragane, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
[Ti] Título:Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report.
[So] Source:J Med Case Rep;11(1):43, 2017 Feb 16.
[Is] ISSN:1752-1947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The safety and efficacy of chemotherapy for patients undergoing concomitant hemodialysis have not been fully established and optimal doses of anti-cancer drugs and best timing of hemodialysis remains unclear. Although chemosensitive cancers, such as germ cell tumors, treated with chemotherapy should have sufficient dose intensity maintained to achieve the desired effect, many patients with cancer undergoing hemodialysis might be under-treated because the pharmacokinetics of anti-cancer drugs in such patients remains unknown. CASE PRESENTATION: We describe a 31-year-old Japanese man with a mediastinal yolk sac tumor treated with surgery followed by five cycles of chemotherapy containing cisplatin and etoposide while concomitantly undergoing hemodialysis. The doses of these agents used in the first cycle were 50% of the standard dose of cisplatin (10 mg/m ) and 60% of the standard dose of etoposide (60 mg/m ) on days 1 through to 5; the doses were subsequently escalated to 75% with both agents. Hemodialysis was started 1 hour after infusions of these agents. Severe hematological toxicities were observed despite successful treatment. During treatment with concurrent hemodialysis, pharmacokinetic analysis of cisplatin was performed and its relationship with adverse effects was assessed. Compared with patients with normal renal function, the maximum drug concentration was higher, and concentration increased in the interval between hemodialysis and the subsequent cisplatin infusion, resulting in a higher area under the curve despite a reduction in the dose to 75% of the standard regimen. CONCLUSIONS: Because of the altered pharmacokinetics pharmacodynamics status of patients with renal dysfunction undergoing hemodialysis, pharmacokinetics pharmacodynamics analysis is deemed to be helpful for effective and safe management of chemotherapy in patients undergoing hemodialysis.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Tumor do Seio Endodérmico/tratamento farmacológico
Neoplasias do Mediastino/tratamento farmacológico
Diálise Renal
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/farmacocinética
Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética
Cisplatino/administração & dosagem
Cisplatino/farmacocinética
Tumor do Seio Endodérmico/metabolismo
Etoposídeo/administração & dosagem
Etoposídeo/farmacocinética
Seres Humanos
Masculino
Neoplasias do Mediastino/metabolismo
Mediastino/diagnóstico por imagem
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 6PLQ3CP4P3 (Etoposide); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170720
[Lr] Data última revisão:
170720
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170217
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1213-7


  7 / 927 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28199346
[Au] Autor:Azzollini J; Pesenti C; Ferrari L; Fontana L; Calvello M; Peissel B; Portera G; Tabano S; Carcangiu ML; Riva P; Miozzo M; Manoukian S
[Ad] Endereço:Medical Genetics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
[Ti] Título:Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.
[So] Source:PLoS One;12(2):e0171663, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In BRCA1/2 families, early-onset breast cancer (BrCa) cases may be also observed among non-carrier relatives. These women are considered phenocopies and raise difficult counselling issues concerning the selection of the index case and the residual risks estimate in negative family members. Few studies investigated the presence of potential genetic susceptibility factors in phenocopies, mainly focussing on BrCa-associated single-nucleotide polymorphisms. We hypothesized that, as for other Mendelian diseases, a revertant somatic mosaicism, resulting from spontaneous correction of a pathogenic mutation, might occur also in BRCA pedigrees. A putative low-level mosaicism in phenocopies, which has never been investigated, might be the causal factor undetected by standard diagnostic testing. We selected 16 non-carriers BrCa-affected from 15 BRCA1/2 families, and investigated the presence of mosaicism through MALDI-TOF mass spectrometry. The analyses were performed on available tumour samples (7 cases), blood leukocytes, buccal mucosa and urine samples (2 cases) or on blood only (7 cases). In one family (n.8), real-time PCR was also performed to analyse the phenocopy and her healthy parents. On the 16 phenocopies we did not detect the family mutations neither in the tumour, expected to display the highest mutation frequency, nor in the other analysed tissues. In family 8, all the genotyping assays did not detect mosaicism in the phenocopy or her healthy parents, supporting the hypothesis of a de novo occurrence of the BRCA2 mutation identified in the proband. These results suggest that somatic mosaicism is not likely to be a common phenomenon in BRCA1/2 families. As our families fulfilled high-risk selection criteria, other genetic factors might be responsible for most of these cases and have a significant impact on risk assessment in BRCA1/2 families. Finally, we found a de novo BRCA2 mutation, suggesting that, although rare, this event should be taken into account in the evaluation of high-risk families.
[Mh] Termos MeSH primário: Proteína BRCA1/genética
Proteína BRCA2/genética
Neoplasias da Mama/genética
Mosaicismo
[Mh] Termos MeSH secundário: Adulto
Neoplasias da Mama/diagnóstico
DNA/análise
DNA/isolamento & purificação
DNA/metabolismo
Tumor do Seio Endodérmico/diagnóstico
Tumor do Seio Endodérmico/genética
Feminino
Testes Genéticos
Genótipo
Seres Humanos
Meia-Idade
Linhagem
Fenótipo
Polimorfismo de Nucleotídeo Único
Reação em Cadeia da Polimerase em Tempo Real
Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
Neoplasias do Colo do Útero/diagnóstico
Neoplasias do Colo do Útero/genética
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (BRCA1 Protein); 0 (BRCA1 protein, human); 0 (BRCA2 Protein); 0 (BRCA2 protein, human); 9007-49-2 (DNA)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170216
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171663


  8 / 927 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28039901
[Au] Autor:Wakiya T; Toyoki Y; Ishido K; Kudo D; Kimura N; Tsutsumi S; Odagiri T; Suto A; Uchida C; Hakamada K
[Ad] Endereço:Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Aomori, Japan.
[Ti] Título:Living donor liver transplantation in a pediatric patient with preexisting yolk sac tumor.
[So] Source:Pediatr Transplant;21(2), 2017 Mar.
[Is] ISSN:1399-3046
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:There is ongoing discussion regarding the indications and timing of LT for patients with a preexisting extrahepatic malignancy. We herein report a pediatric case that underwent LDLT after therapy for YST. The patient, a 13-year-old female with biliary atresia, had undergone portoenterostomy at 2 months of age. She developed a left ovarian tumor with a high serum alpha-fetoprotein concentration at 10 years of age. She underwent left oophorectomy and was diagnosed with ovarian YST (Stage I). After surgery, hepatopulmonary syndrome progressed gradually. She was examined carefully and exhibited no findings to suggest the recurrence of YST. We decided to perform LDLT at 3 years and 6 months of age after the surgery for YST. The patient is currently alive and doing well without recurrence of YST at approximately 2 years after transplantation. There is no significant difference between the recurrence rate of preexisting extrahepatic malignancy and the incidence of de novo malignancy if specific cases are selected. The indications and period from surgery for preexisting extrahepatic malignancy to LT should thus be determined according to the type and stage of cancer.
[Mh] Termos MeSH primário: Atresia Biliar/cirurgia
Tumor do Seio Endodérmico/cirurgia
Transplante de Fígado
Doadores Vivos
Neoplasias Ovarianas/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Atresia Biliar/complicações
Tumor do Seio Endodérmico/complicações
Feminino
Síndrome Hepatopulmonar/diagnóstico
Seres Humanos
Imunossupressão
Estimativa de Kaplan-Meier
Cirrose Hepática/complicações
Cirrose Hepática/cirurgia
Neoplasias Ovarianas/complicações
Período Pós-Operatório
Recidiva
alfa-Fetoproteínas/análise
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (alpha-Fetoproteins)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170518
[Lr] Data última revisão:
170518
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170101
[St] Status:MEDLINE
[do] DOI:10.1111/petr.12856


  9 / 927 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27959583
[Au] Autor:Euscher ED
[Ti] Título:Unusual Presentations of Gynecologic Tumors: Extragonadal Yolk Sac Tumor of the Vulva.
[So] Source:Arch Pathol Lab Med;141(2):293-297, 2017 Feb.
[Is] ISSN:1543-2165
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Extragonadal germ cell tumors are uncommon, and although they morphologically resemble their gonadal counterparts, unexpected gonadal presentation increases the potential for erroneous diagnoses. Yolk sac tumor is a malignant germ cell tumor characterized by an extraembryonic yolk sac line of differentiation, and relative to other germ cell tumors, is characterized by varied and diverse histologic patterns. When occurring outside of typical age parameters or in extragonadal locations, the histologic variability of yolk sac tumor and its tendency to mimic somatic tumors pose diagnostic challenges. Because extragonadal yolk sac tumor of the vulva is very rare, with only isolated case reports and small series in the literature, it is often not considered in the differential diagnosis. As both prognosis and management of yolk sac tumor differ significantly from those of somatic tumors, accurate diagnosis is essential. This review discusses histologic features of extragonadal yolk sac tumor, addresses somatic tumors arising in the vulva for which yolk sac tumor may be confused, and provides guidance with respect to the use of immunohistochemistry in the diagnosis of yolk sac tumor.
[Mh] Termos MeSH primário: Tumor do Seio Endodérmico/patologia
Neoplasias Vulvares/patologia
[Mh] Termos MeSH secundário: Tumor do Seio Endodérmico/diagnóstico
Feminino
Seres Humanos
Neoplasias Vulvares/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161214
[St] Status:MEDLINE
[do] DOI:10.5858/arpa.2016-0151-SA


  10 / 927 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27911225
[Au] Autor:Mukasa A; Yanagisawa S; Saito K; Tanaka S; Takai K; Shibahara J; Ikegami M; Nakao Y; Takeshita K; Matsutani M; Saito N
[Ad] Endereço:Departments of 1 Neurosurgery.
[Ti] Título:Successful treatment of mixed yolk sac tumor and mature teratoma in the spinal cord: case report.
[So] Source:J Neurosurg Spine;26(3):319-324, 2017 Mar.
[Is] ISSN:1547-5646
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary spinal germ cell tumors are rare, and spinal nongerminomatous germ cell tumors represent an even rarer subset for which no standard therapy has been established. The authors report the case of a 24-year-old woman with multifocal primary spinal germ cell tumors scattered from T-12 to L-5 that consisted of yolk sac tumor and mature teratoma. After diagnostic partial resection, the patient was treated with 30 Gy of craniospinal irradiation and 30 Gy of local spinal irradiation, followed by 8 courses of chemotherapy based on ifosfamide, cisplatin, and etoposide (ICE). Salvage surgery was also performed for residual mature teratoma components after the third course of ICE chemotherapy. Chemotherapy was continued after the operation, but ifosfamide was entirely eliminated from the ICE regimen because severe myelosuppression was observed after previous courses. The patient remains recurrence free as of more than 5 years after the completion of chemotherapy. This case suggests that this treatment strategy is an effective option for primary spinal yolk sac tumor.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Tumor do Seio Endodérmico/terapia
Recidiva Local de Neoplasia/terapia
Neoplasias da Medula Espinal/terapia
Teratoma/cirurgia
[Mh] Termos MeSH secundário: Neoplasias Encefálicas/patologia
Neoplasias Encefálicas/terapia
Cisplatino/uso terapêutico
Terapia Combinada
Tumor do Seio Endodérmico/diagnóstico
Etoposídeo/uso terapêutico
Feminino
Seres Humanos
Recidiva Local de Neoplasia/diagnóstico
Neoplasias da Medula Espinal/diagnóstico
Teratoma/diagnóstico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
6PLQ3CP4P3 (Etoposide); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170321
[Lr] Data última revisão:
170321
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161203
[St] Status:MEDLINE
[do] DOI:10.3171/2016.8.SPINE16465



página 1 de 93 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde